This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
« Back
Page 1 of 22

Dendreon's Asset Rummage Sale Completes the Circle of Life

By Adam Feuerstein

Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.

06:01AM 01/30/15

The Absurdity of Flex Pharma IPO: 2 Spices and a Veg Net $86M

By Adam Feuerstein

If the biotech bull market hasn't reached 11 on the absurdity meter quite yet, the Flex Pharma FLKS IPO gets us close.

07:44AM 01/29/15

Aegerion Target of SEC Probe Related to Drug Sales Practices

By Adam Feuerstein

Aegerion slipped disclosure of the SEC probe into an regulatory filing last night.

09:12AM 01/13/15

Bristol-Myers Checkpoint Inhibitor Prolongs Lung Cancer Patient Survival

By Adam Feuerstein

Lung cancer is a larger commercial market opportunity for Bristol's Opdivo and Merck's Keytruda.

07:07AM 01/12/15

'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab

By Adam Feuerstein

Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.

02:56PM 01/09/15

Brainstorm Stem-Cell Therapy Continues to Show Treatment Effect in ALS Patients

By Adam Feuerstein

Final results from a mid-stage study of Brainstorm's NurOwn therapy show a slowing of disease progression in some ALS patients.

10:52AM 01/05/15

Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next

By Adam Feuerstein

U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.

04:16PM 12/19/14

Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators

By Adam Feuerstein

European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.

08:25AM 12/19/14

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

By Adam Feuerstein

One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.

11:20AM 12/16/14

Former Onyx CEO Returns to Biotech to Launch Boston Start Up

By Adam Feuerstein

Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.

09:23AM 12/15/14

« Back
Page 1 of 22

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs